Prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population: Systematic review

Current Diabetes Reviews

Volumn 5, Issue 3, 2009, Pages 171-184

  Linuo, Zhou ^a   Wei, Deng ^b   Lixue, Zhou ^c   Ping, Fang ^d   Daikun, He ^a   Weiwei, Zhang ^a   Kui, Liu ^a   Renming, Hu ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chronic heart failure; Diabetes; Incidence; Prevalence; Risk factors; Systematic review

Indexed keywords

ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

AGE; CARDIOVASCULAR RISK; DIABETIC DIET; DISEASE COURSE; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; ISCHEMIC HEART DISEASE; METABOLIC REGULATION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX; SYSTEMATIC REVIEW; ALBUMINURIA; CHRONIC DISEASE; CORONARY ARTERY DISEASE; METABOLISM;

ALBUMINURIA; BLOOD GLUCOSE; CHRONIC DISEASE; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INCIDENCE; OBESITY; PREVALENCE; RISK FACTORS;

EID: 70349786845     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339909788920938     Document Type: Review

References (59)

1. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003; 26: 2433-2441
2. Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699-703. (Pubitemid 38280536)
3. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 1997; 45: 968-974 (Pubitemid 27330128)
4. Authors/Task Force Members: Karl Swedberg, Chairperson, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005; 26: 1115-1140
5. Dongfeng G, Guangyong H, He J, et al. The survey of epidemic and prevalence of congestive heart failure in china. Study of Cardiovascular Disease in Asia (InterAsia). Zhong Hua Xin Xue Guan Bing Za Zhi 2003; 1: 29-33.
6. Kannel WB, Hjortland M, Castelli WP, et al. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34(1): 29-34.
7. Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345-2351 (Pubitemid 41384275)
8. Thrainsdottir IS, Aspelund T, Geirsson GT, et al. The association between glucose abnormalities and heart failure in the population-based reykjavik study. Diabetes Care 2005; 28: 612-616 (Pubitemid 40315321)
9. Nichols GA, Hillier TA, Erbey JR, et al. Congestive Heart Failure in Type 2 Diabetes Prevalence, incidence, and risk factors. Diabetes Care 2001; 24: 1614-1619 (Pubitemid 33716458)
10. Bouma M, Dekker JH, van Eijk JT, et al. Metabolic control and morbidity of Type 2 diabetic patients in a general practice net work. Fam Pract 1999; 16: 402-406 (Pubitemid 29410762)
11. Barzilay JI, Kronmal RA, Gottdiener JS, et al. The association of fasting glucose levels with congestive heart failure in diabetic adults > or =65 years: the Cardiovascular Health Study. J Am Coll Cardiol 2004; 43: 2236-2241
12. Vaur L, Gueret P, Lievre M, et al. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 Diabetes, Hypertension, Cardio- vascular Events and Ramipril) study. Diabetes Care 2003; 26: 855-860 (Pubitemid 36929355)
13. Aronow WS, Ahn C. Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. Chest 1999; 115: 867-868
14. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668-2673 (Pubitemid 32538780)
15. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258): 405-412 (Pubitemid 30609442)
16. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and micro- vascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321; 412-419 (Pubitemid 30609443)
17. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426 (Pubitemid 32681484)
18. Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004; 27: 1879-1884 (Pubitemid 38989226)
19. Maru S, Koch GG, Stender M, et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care 2005; 28: 20-26 (Pubitemid 40095777)
20. Schindler DM, Kostis JB, Yusuf S, et al. For the SOLVD investigators. Diabetes mellitus: a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol 1996; 77: 1017-1020 (Pubitemid 26158096)
21. Melchior T, Rask-Madsen C, Torp-Pedersen C, et al. The impact of heart failure on prognosis of diabetic and non-diabetic patients with myocardial infarction: a 15-year follow-up study. Eur J Heart Fail 2001; 3: 83-90. (Pubitemid 32127114)
22. Gerstein HC, Pogue J, Mann JFE, et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005; 48: 1749-1755 (Pubitemid 41317828)
23. The Action to Control Cardiovascular Risk in Diabetes Study Group*. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008; 358: 2545-2559
24. Pan CY. The current situation of blood glucose control in China - the survey of state of diabetes therapy in Asia. The results of years of 1998, 2001 and 2003. Section Endocrinol Foreign Med Sci 2005; 25: 174-178
25. Shanghai heart failure survey group. The survey of epidemiology and the state of therapy of hospitalize CHF patient in Shanghai 1980, 1990, 2000 year. Zhonghua Xin Xue Guan Bing Za Zhi 2002; 30: 24-27
26. Natali A, Vichi S, Landi P, et al. Coronary atherosclerosis in type 2 diabetes: Angiographical findings and clinical outcome. Diabetologia 2000; 43: 632-641 (Pubitemid 30322081)
27. Lindvall B, Brorsson B, Herlitz J, et al. Comparison of diabetic and non-diabetic patients referred for coronary angiography. Int J Cardiol 1999; 70: 33-42. (Pubitemid 29277109)
28. Xuehong D, Linuo Z, Yingjiu Z, et al. Impaired fasting glucose and the severity of angiographic coronary artery disease in high-risk Chinese patients. Metabolism 2008; 57: 24-29
29. Yingjiu Z, Xuehong D, Linuo Z, et al. The impact of type 2 diabetes on the severity of coronary artery disease. Chin J Cardiovascol 2005; 10: 195-197
30. Agha W, Haider, Martin G, Larson. Systolic Blood Pressure, Diastolic Blood Pressure, and Pulse Pressure as Predictors of Risk for Congestive Heart Failure in the Framingham Heart Study. Ann Int Med 2003; 138: 10-16
31. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1214-1218 (Pubitemid 26117716)
32. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-313
33. Yongxin L. From left ventricular hypertrophy to congestive heart failure. Chin J Hypertens 2007; 15: 189-199
34. Okin PM, Devereux RB, Gerdts E, et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation 2006; 113: 1588-1596 (Pubitemid 43739418)
35. Carr AA, Kowey PR, Deverux RB, et al. Hospitalization for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE Studies. Am J Cardiol 2005; 96: 1530-1536
36. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin- dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652
37. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Int Med 2003; 138: 542-549 (Pubitemid 38124675)
38. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781 (Pubitemid 37093918)
39. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997
40. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Int Med 1997; 157: 1413-1418 (Pubitemid 27300386)
41. Agewall S, Wikstrand J, Ljungman S, et al. On behalf of the Risk Factor Intervention Study Group: Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am J Cardiol 1997; 80: 164-169
42. Gerstein HC, Mann JF, Pogue J, et al. For the HOPE Study investigators. Prevalence and determinants of MA in high-risk diabetic and non diabetic patients in the Heart Outcomes Prevention Evaluation Study. Diabetes Care 2000; 23: B35-B3.
43. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, et al. Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992-1997 (Pubitemid 29379934)
44. Thrainsdottir IS, Aspelund T, Gudnason V, et al. Increasing glucose levels and BMI predict future heart failure experience from the Reykjavík Study. Eur J Heart Fail 2007; 9: 1051-1057 (Pubitemid 47454776)
45. Lee DS, Massaro JM, Wang TJ, et al. Antecedent blood pressure, body mass index, and the risk of incident heart failure in later life. Hypertension 2007; 50: 869-876
46. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-313
47. Murphy NF, MacIntyre K, Stewart S, et al. Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J 2006; 27: 96-106. (Pubitemid 41785938)
48. Lakka HM, Lakka TA, Tuomilehto J, et al. Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J 2002; 23: 706-713 (Pubitemid 35230700)
49. Young ME, Guthrie PH, Razeghi P, et al. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 2002; 51: 2587-2595 (Pubitemid 34827411)
50. Weiwei Z, Dong W, Linuo Z, et al. Light and electron microscopic changes of diabetic cardiomyopathy in OLETF diabetic rats. Fudan Univ J Med Sci 2008; 35: 943-948
51. Ingelsson E, Sundström J, Arnlöv J, et al. Insulin resistance and risk of congestive heart failure. JAMA 2005; 20(294): 334-341 (Pubitemid 41043777)
52. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106: 3068-3072 (Pubitemid 35440290)
53. Frazier CG, Alexander KP, Newby LK, et al. Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials. J Am Coll Cardiol 2007; 49: 1450-1458
54. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-1402 (Pubitemid 35239711)
55. Rich MW. Heart failure in older adults. Med Clin North Am 2006; 90: 863-885
56. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007; 335: 497-507.
57. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471 (Pubitemid 46919772)
58. Eriksson H, Svardsudd K, Larssonj B, et al. Risk factors for heart failure in the general population: The study of men born in 1913. Eur Heart J 1989; 10: 647-656
59. He J, Ogden LG, Lydia AB, et al. Risk Factors for Congestive Heart Failure in US Men and Women (NHANES I Epidemiologic Follow-up Study). Arch Int Med 2001; 161: 996-1002. (Pubitemid 32295654)